Quick Recap
Neurology System, Protocol 2/12. Spontaneous Intracerebral Hemorrhage (ICH). Aneurysmal SAH has its own dedicated protocol.
1. Definition & Epidemiology
ICH = focal collection of blood within brain parenchyma, +/- extension into ventricles, subarachnoid, or subdural spaces. US incidence 23.15/100,000/year, rising ~11% over 15 years (paralleling hypertension and anticoagulation prevalence). Second most common stroke subtype (10-15% of all strokes), disproportionately affecting Black and Asian populations. One of the worst-prognosis acute neurologic disorders: 40% case fatality at 1 month, 54% at 1 year; only 27% achieve functional independence at 3 months.
2. Pathophysiology
Brain injury occurs via three mechanisms: (1) direct mechanical dissection of neuronal pathways/tissue by the expanding hematoma, (2) mass effect raising ICP -> adjacent tissue damage and/or herniation, (3) toxic blood degradation products driving cerebral edema, seizures, fever, and autonomic instability. Early hematoma growth/rebleeding occurs in ~1/3 of patients, even WITHOUT coagulopathy — mostly within the first 6 hours but possible up to 24 hours — and is directly associated with clinical deterioration and worse outcomes, which is why the acute phase demands aggressive early monitoring regardless of anticoagulation status.
3. Presentation
Classic tetrad: headache (~30% of patients), altered consciousness (majority present with depressed LOC), nausea/vomiting (especially posterior fossa ICH from vestibular/4th ventricle involvement, but also a sign of rising ICP in supratentorial ICH), and focal neurologic deficits per hematoma location. Seizures (focal or generalized) associated with cortical involvement.
4. Etiology Clues (Primary vs Secondary ICH)
Etiology | Clinical clues | Imaging findings |
Hypertensive (most common primary) | Chronic HTN history | Typical deep locations (putamen, thalamus, pons, cerebellum) |
Cerebral amyloid angiopathy (CAA) | Older patients, lobar hemorrhage, may be recurrent | Lobar location, may see prior microbleeds |
Coagulopathy | Anticoagulant use | Lobulated, fluid-fluid levels within hematoma |
Vascular malformation (AVM, cavernous malformation, aneurysm, mycotic aneurysm, dural AV fistula) | Younger (<45y), normotensive, family history, prior seizure/hemorrhage same region | Typical findings on CTA/MRA/DSA |
Moyamoya | Black/Asian ethnicity, sickle cell disease | "Puff of smoke" on DSA; may also cause infarcts, IVH, SAH |
Hemorrhagic conversion of ischemic stroke | Prior ischemic stroke | Petechial, patchy hemorrhages scattered through infarcted tissue, infarct outline visible |
Cerebral venous sinus thrombosis | Eclampsia, pregnancy, subacute headache | Noncontrast CT sinus hyperdensity; CT/MR venogram filling defect |
Cerebral vasculitis | Young, headache/prior stroke history | Nonspecific; multi-region infarcts/white matter disease |
Tumor | Known primary, prior hemorrhage same territory | Significant surrounding edema, contiguous contrast enhancement |
5. Immediate Stabilization (ABCDE)
A patient with suspected ICH is a neurologic emergency requiring expedited medical stabilization BEFORE diagnostic imaging given significant risk of early deterioration/cardiorespiratory compromise.
Airway: brief assessment of ability to protect airway; rapid sequence intubation for impaired arousal with aspiration/hypoxemia/hypercarbia risk. Choose induction agents that minimize ICP rise during laryngoscopy: pretreat with lidocaine 1.5mg/kg 2-3 minutes before intubation (mitigates ICP rise); etomidate preferred given minimal BP impact, barring contraindications.
Circulation — BP management (evidence-based but with acknowledged limits):
- Extreme BP elevation immediately post-ICH is thought to increase early neurologic deterioration/hematoma expansion risk, but robust evidence proving reduced hematoma expansion from aggressive BP reduction is lacking
- Based on INTERACT-2 and ATACH-2 trial data: lowering SBP to a target of 140 mmHg is SAFE but NOT associated with improved functional outcome in mild-moderate ICH presenting with SBP 150-220
- Acute lowering of SBP below 140 mmHg is potentially HARMFUL and should be avoided
- Preferred agents: IV beta-blockers or calcium channel blockers (short-acting, rapidly titratable); avoid nitrates (cerebral vasodilation risk, same rationale as ischemic stroke); address pain, which itself elevates BP
Coagulopathy correction — STOP all antiplatelet/anticoagulant agents immediately, then reverse:
Agent | Reversal |
Warfarin | Vitamin K 10mg IV/enteral daily x3 days PLUS PCC (preferred over FFP — faster, less volume): INR 2-3.9 = 25 units/kg (max 2500); INR 4-6 = 35 units/kg (max 3500); INR >6 = 50 units/kg (max 5000). FFP 15-20mL/kg as alternative if PCC unavailable |
LMWH (last dose <8h) | Protamine 1mg/100 anti-Xa units (max 50mg) |
Dabigatran | Idarucizumab 5g once |
Apixaban/rivaroxaban | Activated charcoal if last dose <2h; Andexanet alfa (low dose 400mg bolus + 4mg/min infusion if >8h from last dose; high dose 800mg bolus + 8mg/min infusion if <8h from last dose) — superiority over PCC not yet established; PCC 50 units/kg (max 5000) as alternative |
Thrombocytopenia/factor deficiency | Platelet and coagulation factor replacement as needed |
Follow coagulation panel frequently, keep corrected for 24-48h.
Platelet transfusion: consider ONLY for spontaneous ICH on antiplatelet agents requiring emergent neurosurgery (reduces postop bleeding/mortality in that specific context) — platelet transfusion outside this setting or without thrombocytopenia is associated with INCREASED mortality and should be avoided.
Checklist:
6. Investigations
Non-contrast head CT: first-line, rapid, 89% sensitive/100% specific for acute ICH within the first week; localizes hematoma, detects IVH extension, estimates volume.
"Spot sign" (contrast extravasation into the hematoma on CT with contrast) associated with hematoma expansion in ~60% of patients — a marker of ongoing active bleeding risk.
CT angiography: 97% sensitivity/98.9% specificity for causal vascular abnormalities vs DSA (gold standard) — obtain when secondary etiology suspected (Section 4 clues).
History focus: anticoagulant use, recent head trauma, illicit drug use, hypertension history, prior stroke.
7. Severity Assessment — Validated Scores
ICH Score (Hemphill et al., 0-6 points, predicts 30-day mortality):
Component | Points |
GCS 3-4 | 2 |
GCS 5-12 | 1 |
GCS 13-15 | 0 |
ICH volume >30cm3 | 1 |
IVH present | 1 |
Infratentorial origin | 1 |
Age >80 | 1 |
30-day mortality by score: 0 = 0%, 1 = 13%, 2 = 26%, 3 = 72%, 4 = 97%, 5 = 100%.
Hematoma volume (ABC/2 method): A = largest diameter on the axial slice with maximal hematoma area; B = largest diameter perpendicular to A; C = number of CT slices with visible hemorrhage x slice thickness (typically 0.3-0.5cm). Volume (mL) = (A x B x C)/2.
FUNC Score (predicts 90-day functional independence, 0-11 points): ICH volume (<30=4, 30-60=2, >60=0), age (<70=2, 70-79=1, >=80=0), location (lobar=2, deep=1, infratentorial=0), GCS (>=9=2, <=8=0), pre-ICH cognitive impairment (no=1, yes=0). 90-day functional independence by score: 0-4=0%, 5-7=1-20%, 8=21-60%, 9-10=61-80%, 11=81-100%.
8. Neurosurgical Intervention
Indications for neurosurgical intervention: posterior fossa or temporal lobe hemorrhage >3cm; ICH causing hydrocephalus or brainstem compression; hydrocephalus/IVH requiring EVD; complicated cases requiring ICP monitoring.
Cerebellar hemorrhage with neurologic deterioration, brainstem compression, or hydrocephalus: surgical evacuation recommended AS SOON AS POSSIBLE — clear, time-critical indication, unlike supratentorial ICH.
Supratentorial ICH surgical management remains CONTROVERSIAL due to lack of strong evidence for conventional craniotomy with evacuation.
Minimally invasive surgery (MIS) (endoscopic or stereotactic aspiration, +/- thrombolytic use) shows promising results — relieves hematoma pressure/perihematomal edema with less healthy tissue disruption than craniotomy; appears safe and may reduce mortality, though functional outcome benefit evidence is weaker. The 2022 AHA/ASA ICH guideline supports MIS over conventional craniotomy with evacuation where surgical intervention is pursued for supratentorial ICH.
9. ICP Management
Hydrocephalus complicates up to 50% of ICH cases, associated with younger age, lower GCS, deep hemorrhages, intubation, and mortality. Consider ICP monitoring via ventricular catheter for: GCS <=8, clinical herniation evidence, or significant IVH/hydrocephalus. ICP >20mmHg seen in ~70% of one retrospective cohort, most common in young patients with supratentorial hemorrhage. Treat elevated ICP with hyperosmolar agents (mannitol/hypertonic saline), CSF diversion via ventriculostomy, sedation, or therapeutic hypothermia — see the dedicated Raised ICP protocol for the full treatment algorithm.
10. Seizures
Occur in 5-15% of ICH patients, usually within the first few days. Seizure PROPHYLAXIS is NOT indicated — available evidence fails to show improved functional outcomes, seizure control, or mortality benefit (same principle as ischemic stroke). Continuous EEG should be considered for depressed mental status out of proportion to injury severity, or fluctuating exam — nonconvulsive seizures are a real, easily missed cause of unexplained depressed consciousness in ICH. Treat clinical seizures AND electrographic seizures with mental status change with anticonvulsants (see Status Epilepticus protocol); do not treat prophylactically.
11. Fever
Common after ICH and independently associated with worse outcome — treat aggressively. Sustained temp >38.5C: acetaminophen, chilled saline, cooling blankets, PLUS a thorough infectious source workup. Medically refractory fever: consider surface, esophageal, or endovascular cooling with heat-exchange catheters. "Fever of central origin" is a diagnosis of exclusion, seen more with IVH extension and pontine hemorrhage specifically.
12. General Care / VTE Prophylaxis / Anticoagulation Resumption
Standard ICU complication vigilance (MI, HF/pulmonary edema, DVT, aspiration pneumonia, UTI, pressure ulcers, contractures). Sequential compression devices from admission; pharmacologic VTE prophylaxis (LMWH or UFH) can start after 48 hours IF no evidence of hematoma expansion — do not start pharmacologic prophylaxis before this window or before confirming stability.
Long-term anticoagulation resumption:
- Lobar ICH with probable CAA carries high recurrence risk — AVOID long-term anticoagulation for indications like nonvalvular AFib in these patients specifically
- Clear anticoagulation indication (e.g., mechanical valve) or antiplatelet indication (e.g., coronary stent): reasonable to restart anticoagulation in NON-lobar ICH at 1-4 weeks, and restart antiplatelet therapy in ALL ICH types, once bleeding cessation is documented
13. Organ Support
ICP management per Section 9/Raised ICP protocol; mechanical ventilation with ICP-conscious strategy; blood pressure control per Section 5; standard ICU supportive care with the specific VTE prophylaxis timing caveat above.
14. Consultation Matrix
Consultation | Trigger | Timing |
Neurosurgery | Cerebellar hemorrhage with deterioration/compression/hydrocephalus, MIS candidacy, ICP monitoring need | Immediate |
Neurology/Neurocritical Care | All ICH admissions | Immediate |
Hematology | Complex coagulopathy reversal | Urgent |
15. Monitoring Framework
Serial neuro checks (frequent, given the ~1/3 early hematoma expansion risk within 6-24h), repeat CT to assess for expansion (especially if clinical change or "spot sign" present), ICP monitoring if indicated, temperature (active control), continuous EEG if indicated, coagulation panel trend during reversal (keep corrected 24-48h).
16. ICU Bundle Checklist (Daily)
17. Complications
Early hematoma expansion/rebleeding (~1/3 of patients), hydrocephalus (~50%), elevated ICP/herniation, seizures, fever-associated worsened outcomes, standard ICU complications (VTE, aspiration, pressure injury). Prevention: appropriate BP target, prompt coagulopathy reversal, ICP monitoring in high-risk patients, delayed VTE prophylaxis timing. Rescue: neurosurgical evacuation/EVD per indications, ICP-directed therapy, cooling for refractory fever.
18. Escalation & De-escalation
Escalate: new/worsening deficit, declining GCS -> immediate repeat imaging, ICP monitoring/treatment, neurosurgical evaluation.
De-escalate: stable/improving neuro exam, no expansion on repeat imaging, ICP controlled or not elevated -> transition BP target toward standard goals, initiate VTE prophylaxis per timing criteria, begin anticoagulation/antiplatelet resumption discussion per indication and ICH location.
19. ICU Discharge Criteria
Neurologically stable, hematoma stable on repeat imaging, ICP controlled/resolved, coagulopathy corrected, fever controlled, VTE prophylaxis established, anticoagulation resumption plan (if applicable) documented, rehabilitation planning underway.
20. Documentation & Medicolegal Checklist
21. Key Guidelines
Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage. Stroke. 2022;53(7):e282-e361 (AHA/ASA) — primary current reference.
22. Landmark Trials
INTERACT-2 and ATACH-2: intensive (target SBP 140) vs standard BP lowering in acute ICH — intensive lowering to 140 is SAFE but did not improve functional outcome; established the current "140, not lower" target and the caution against overcorrection.
Hemphill JC 3rd, Bonovich DC, Besmertis L, et al. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32(4):891-897 (original derivation).
23. Controversies
Surgical management of supratentorial ICH remains genuinely unresolved — conventional craniotomy lacks strong evidence, and while MIS is increasingly favored (now guideline-supported over craniotomy when surgery is pursued), the exact functional-outcome benefit magnitude varies across studies and patient selection criteria are still evolving. The precise BP target below 140 that becomes harmful is not sharply defined — "potentially harmful" is based on trial-level signal rather than a hard physiologic cutoff. Anticoagulation resumption timing (1-4 weeks for non-lobar ICH) is guideline-based consensus rather than derived from dedicated RCTs in this specific population.
24. References
- Castro-Apolo RG, Keyrouz SG. Intracerebral Hemorrhage. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 57).
- Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage. Stroke. 2022;53(7):e282-e361.
- Hemphill JC 3rd, Bonovich DC, Besmertis L, et al. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32(4):891-897.
- Qureshi AI, Palesch YY, Barsan WG, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage (ATACH-2). N Engl J Med. 2016;375(11):1033-1043.
- Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage (INTERACT2). N Engl J Med. 2013;368(25):2355-2365.